

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 78011

Title: Effectiveness and safety of generic and brand direct acting antivirals for the treatment of chronic hepatitis C

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02528485

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: Bahrain

Manuscript submission date: 2022-07-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-07-15 08:00

Reviewer performed review: 2022-07-18 08:16

Review time: 3 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

This study intended to compare the efficacy and safety of generic versus brand DAAs for hepatitis C treatment in Bahrain. They found that treatment of chronic hepatitis C patients with generic and brand DAAs demonstrated comparable effectiveness and safety. Several suggestions: 1. In the [study design], please write down the certificate number after [approval for the study was received from the Institutional Review Board of the hospital]. 2. In the [Treatment groupings], please mention what are the generic DAAs, for example, the different generic sofosbuvir(s) used in reference 16 were written. 3. In the [Measurements], please change [real time polymerase chain reaction (PCR)] to [real time reverse transcriptase-polymerase chain reaction (real-time RT-PCR)]. 4. In Table 1, [original] may change to [brand]. 5. Please check ref. 17 and 18, I could not find them in PubMed.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 78011

Title: Effectiveness and safety of generic and brand direct acting antivirals for the treatment of chronic hepatitis C

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05231434

Position: Associate Editor

Academic degree: BM BCh, MD, MSc

Professional title: Full Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: Bahrain

Manuscript submission date: 2022-07-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-07-21 09:08

Reviewer performed review: 2022-07-21 09:34

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

I have reviewed the article entitled "Effectiveness and safety of generic and brand direct acting antivirals for the treatment of chronic hepatitis C". The article has many weak points and flaws. The literature is full of articles discussing the same points with huge number of cases. Also, the retrospective nature of the study carries many biases, and the cases were already treated 5 years ago!! I can't see any benefits from publishing the results of this work.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 78011

Title: Effectiveness and safety of generic and brand direct acting antivirals for the treatment of chronic hepatitis C

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05121991

Position: Peer Reviewer

Academic degree: MD

Professional title: Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: Bahrain

Manuscript submission date: 2022-07-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-07-21 02:48

Reviewer performed review: 2022-07-30 00:00

Review time: 8 Days and 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

As regard the article entitled (Effectiveness and safety of generic and brand direct acting antivirals for the treatment of chronic hepatitis C) although it is not novel but important in the field of viral eradication of HCV as it compare between generic and brand DAAs in treatment of HCV as one of the main barriers in low income countries is the cost of treatment. but some comments to be considered: - patients and methods defenition of chronic HCV must be positive PCRHCV for more than 6 months - The groups must be classified into Cirrhotic and non cirrhotic and every group must be further classified into naive and experienced patients because each group has specific line of treatment and so the response will be diffidently differ so theses data must be presented in tables .

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 78011

Title: Effectiveness and safety of generic and brand direct acting antivirals for the treatment of chronic hepatitis C

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06101850

Position: Peer Reviewer

Academic degree: MD

Professional title: Adjunct Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: Bahrain

Manuscript submission date: 2022-07-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-07-20 21:59

Reviewer performed review: 2022-07-30 09:56

Review time: 9 Days and 11 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The manuscript is very well written in clear language. The study addresses an important issue which the use of generic DAAs especially in low income countries. There are some points that need to be clarified: 1. Was this a retrospective or a prospective study. 2. Was HBV excluded 3. The criteria used to select patients to either generic or brand DAAs. 4. Was there any drop outs , what are the adverse effects encountered. 5. A more detailed history of previous antiviral drugs used and causes of previous treatment failures. 6. An explanation of the difference in SVR between generic and brand DAAs.